| Name | Title | Contact Details |
|---|
Wellpath is the premier provider of localized, high-quality, compassionate care to vulnerable patients in challenging clinical environments. Wellpath holds patients at the center of everything we do and promotes rigorous standards of care and innovation. With nearly 15,000 clinicians and professionals in 35 states across the U.S. and Australia, Wellpath provides medical and mental healthcare services for over 240,000 patients daily in state hospitals, forensic treatment, civil commitment centers, community care centers as well as local, state and federal correctional facilities.
PIXI is a Culver City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Seniorlink is a tech-enabled health services company transforming care management in the home. For over 15 years, we`ve pioneered solutions for caregivers, including our compassionate technology of Vela, and our unique in-home model of Caregiver Homes. These innovative approaches have earned Caregiver Homes recognition as the first community-based organization to receive the National Committee for Quality Assurance`s (NCQA) highest level of accreditation for Case Management. Today, we remain fully committed to caregivers, supporting them at every step with resources, advocacy and insights as they fulfill their promise to a loved one. We value your contribution to this important mission, and look forward to having you join our team.
L.A.C. Communications is a Garnerville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.